Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Xgeva Rejection Shows What’s Needed For Non-Metastatic CRPC Approvals

This article was originally published in The Pink Sheet Daily

Executive Summary

As expected, FDA rejected the new indication for Amgen’s bone drug Xgeva in prevention of bone metastases. But the door is still open for other therapies for castration resistant prostate cancer to target earlier stages of disease.


Related Content

Amgen’s Xgeva Gains FDA Nod For Use In Rare Bone Tumor
Momentum In Prostate Cancer Therapy Moves Up To First-Line CRPC
NICE Backs Xgeva for Oncology But Excludes Prostate Cancer Indication
Amgen Rethinks Ganitumab After Longshot Pancreatic Cancer Trial Fails
NCI Expert Drafts Roadmap For Metastasis-Prevention Trials
Zytiga Study Supports Expansion To Early Patient Population
Amgen Needs To Show Xgeva Does More Than Delay Bone Metastases, ODAC Says
Medivation Aims To Capture Prostate Cancer Market, One Trial At A Time
Amgen's Bone Drug Xgeva Delays Pain From Prostate Cancer Metastases
Prostate Cancer Market Snapshot: More Than Provenge


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts